Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults - PubMed
4 hours ago
- #GLP-1 agonists
- #cardiovascular outcomes
- #obesity treatment
- Tirzepatide showed lower 12-month cardiovascular event rates compared to semaglutide (1.90% vs. 2.18%) in non-diabetic adults with obesity.
- New-onset heart failure was significantly reduced with tirzepatide versus semaglutide (1.04% vs. 1.29%).
- No significant differences were found in all-cause mortality, acute coronary syndrome, or stroke between the two treatments.
- Tirzepatide achieved greater weight loss than semaglutide (-9.8 kg vs. -8.0 kg).
- Adverse event rates were similar between tirzepatide and semaglutide, with no new safety concerns identified.